Patent Grant
7533667
1. Field of the Invention
The present invention relates to systems and methods for removing trapped air in emphysematous lungs, and more particularly, to systems and methods for removing trapped air in emphysematous hyperinflated lungs by bypassing non-patent airways via a conduit through the outer pleural layer of the lung to a containment/trap device. The present invention also relates to a collateral ventilation bypass system that utilizes the trachea for expelling trapped air rather than a containment/trap device. The present invention also relates to a device and methodology to assist in pulmonary decompression. The present invention also relates to systems and methods for chemical pleurodesis.
2. Discussion of the Related Art
As a result of studies that date back to the 1930's and particularly studies conducted in the 1960's and early 1970's, it has been determined that long-term continuous oxygen therapy is beneficial in the treatment of hypoxemic patients with chronic obstructive pulmonary disease. In other words, a patient's life and quality of life can be improved by providing a constant supplemental supply of oxygen to the patient's lungs.
However, with the desire to contain medical costs, there is a growing concern that the additional cost of providing continuous oxygen therapy for chronic lung disease will create an excessive increase in the annual cost of oxygen therapy. Thus, it is desirable that oxygen therapy, when provided, be as cost effective as possible.
The standard treatment for patients requiring supplemental oxygen is still to deliver oxygen from an oxygen source by means of a nasal cannula. Such treatment, however, requires a large amount of oxygen, which is wasteful and can cause soreness and irritation to the nose, as well as being potentially aggravating. Other undesirable effects have also been reported. Various other medical approaches which have been proposed to help reduce the cost of continuous oxygen therapy have been studied.
Various devices and methods have been devised for performing emergency cricothyroidotomies and for providing a tracheotomy tube so that a patient whose airway is otherwise blocked may continue to breath. Such devices are generally intended only for use with a patient who is not breathing spontaneously and are not suitable for the long term treatment of chronic lung disease. Typically, such devices are installed by puncturing the skin to create a hole into the cricoid membrane of the larynx above the trachea into which a relatively large curved tracheotomy tube is inserted. As previously described, the use of such tubes has been restricted medically to emergency situations where the patient would otherwise suffocate due to the blockage of the airway. Such emergency tracheotomy tubes are not suitable for long term therapy after the airway blockage is removed.
Other devices which have been found satisfactory for emergency or ventilator use are described in U.S. Pat. Nos. 953,922 to Rogers; 2,873,742 to Shelden; 3,384,087 to Brummelkamp; 3,511,243 to Toy; 3,556,103 to Calhoun; 2,991,787 to Shelden, et al; 3,688,773 to Weiss; 3,817,250 to Weiss, et al.; and 3,916,903 to Pozzi.
Although tracheotomy tubes are satisfactory for their intended purpose, they are not intended for chronic usage by outpatients as a means for delivering supplemental oxygen to spontaneously breathing patients with chronic obstructive pulmonary disease. Such tracheotomy tubes are generally designed so as to provide the total air supply to the patient for a relatively short period of time. The tracheotomy tubes are generally of rigid or semi-rigid construction and of caliber ranging from 2.5 mm outside diameter in infants to 15 mm outside diameter in adults. They are normally inserted in an operating room as a surgical procedure or during emergency situations, through the crico-thyroid membrane where the tissue is less vascular and the possibility of bleeding is reduced. These devices are intended to permit passage of air in both directions until normal breathing has been restored by other means.
Another type of tracheotomy tube is disclosed in Jacobs, U.S. Pat. Nos. 3,682,166 and 3,788,326. The catheter described therein is placed over 14 or 16 gauge needle and inserted through the crico-thyroid membrane for supplying air or oxygen and vacuum on an emergency basis to restore the breathing of a non-breathing patient. The air or oxygen is supplied at 30 to 100 psi for inflation and deflation of the patient's lungs. The Jacobs catheter, like the other tracheotomy tubes previously used, is not suitable for long term outpatient use, and could not easily be adapted to such use.
Due to the limited functionality of tracheotomy tubes, transtracheal catheters have been proposed and used for long term supplemental oxygen therapy. For example the small diameter transtracheal catheter (16 gauge) developed by Dr. Henry J. Heimlich (described in THE ANNALS OF OTOLOGY, RHINOLOGY & LARYNGOLOGY, November-December 1982; Respiratory Rehabilitation with Transtracheal Oxygen System) has been used by the insertion of a relatively large cutting needle (14 gauge) into the trachea at the mid-point between the cricothyroid membrane and the sternal notch. This catheter size can supply oxygen up to about 3 liters per minute at low pressures, such as 2 psi which may be insufficient for patients who require higher flow rates. It does not, however, lend itself to outpatient use and maintenance, such as periodic removal and cleaning, primarily because the connector between the catheter and the oxygen supply hose is adjacent and against the anterior portion of the trachea and cannot be easily seen and manipulated by the patient. Furthermore, the catheter is not provided with positive means to protect against kinking or collapsing which would prevent its effective use on an outpatient basis. Such a feature is not only desirable but necessary for long term outpatient and home care use. Also, because of its structure, i.e. only one exit opening, the oxygen from the catheter is directed straight down the trachea toward the bifurcation between the bronchi. Because of the normal anatomy of the bronchi wherein the left bronchus is at a more acute angle to the trachea than the right bronchus, more of the oxygen from that catheter tends to be directed into the right bronchus rather than being directed or mixed for more equal utilization by both bronchi. Also, as structured, the oxygen can strike the carina, resulting in an undesirable tickling sensation and cough. In addition, in such devices, if a substantial portion of the oxygen is directed against the back wall of the trachea causing erosion of the mucosa in this area which may cause chapping and bleeding. Overall, because of the limited output from the device, it may not operate to supply sufficient supplemental oxygen when the patient is exercising or otherwise quite active or has severe disease.
Diseases associated with chronic obstructive pulmonary disease include chronic bronchitis and emphysema. One aspect of an emphysematous lung is that the communicating flow of air between neighboring air sacs is much more prevalent as compared to healthy lungs. This phenomenon is known as collateral ventilation. Another aspect of an emphysematous lung is that air cannot be expelled from the native airways due to the loss of tissue elastic recoil and radial support of the airways. Essentially, the loss of elastic recoil of the lung tissue contributes to the inability of individuals to exhale completely. The loss of radial support of the airways also allows a collapsing phenomenon to occur during the expiratory phase of breathing. This collapsing phenomenon also intensifies the inability for individuals to exhale completely. As the inability to exhale completely increases, residual volume in the lungs also increases. This then causes the lung to establish in a hyperinflated state where an individual can only take short shallow breaths. Essentially, air is not effectively expelled and stale air accumulates in the lungs. Once the stale air accumulates in the lungs, the individual is deprived of oxygen.
Currently, treatments for chronic obstructive pulmonary disease include bronchodilating drugs, oxygen therapy as described above, and lung volume reduction surgery. Bronchodilating drugs only work on a percentage of patients with chronic obstructive pulmonary disease and generally only provides short term relief. Oxygen therapy is impractical for the reasons described above, and lung volume reduction surgery is an extremely traumatic procedure that involves removing part of the lung. The long term benefits of lung volume reduction surgery are not fully known.
Accordingly, there exists a need for increasing the expiratory flow from an individual suffering from chronic obstructive pulmonary disease. In addition, there exists a need for a minimally invasive means for removing trapped air from the lung or lungs that would allow healthy lung tissue to better ventilate.
The present invention overcomes the disadvantages associated with treating chronic obstructive pulmonary disease, as briefly described above, by utilizing the phenomenon of collateral ventilation to increase the expiratory flow from a diseased lung. The present invention also provides a means for assisting in pulmonary decompression to compress the diseased area or area of the lung or lungs to a smaller volume.
In accordance with a first aspect, the present invention is directed to a pulmonary decompression assist device. The device comprising at least one first member in fluid communication, at a predetermine site, within a lung of a patient, a sealing device for establishing an airtight seal between the at least one first member and the lung, and a second member connected to the at least one first member, the second member comprising an apparatus for drawing air from the lung of the patient through the at least one first member and venting it to an area external of the lung.
In accordance with a second aspect, the present invention is directed to a pulmonary decompression assist device. The device comprising at least one first member in fluid communication, at a predetermined site, within a lung of a patient, a first sealing device for establishing an airtight seal between the at least one first member and the lung, a second member connected to and in fluid communication with the at least one first member, the second member comprising an apparatus for drawing air from the lung of the patient through the at least one first member and expelling it to the ambient environment, the second member including a section positioned external of the body of the patient, and a second sealing device for sealing the section positioned external of the body of the patient to the body.
In accordance with a third aspect, the present invention is directed to a method for decompressing a hyperinflated portion of a lung of a patient. The device comprising, determining a site of hyperinflation in a patient's lung, creating a pressure differential between the hyperinflated portion of the lung and the ambient environment such that air from the hyperinflated portion of the lung is vented to the ambient environment.
The long term oxygen therapy system of the present invention delivers oxygen directly to diseased sites in a patient's lungs. Long term oxygen therapy is widely accepted as the standard treatment for hypoxia caused by chronic obstructive pulmonary disease, for example, pulmonary emphysema. Pulmonary emphysema is a chronic obstructive pulmonary disease wherein the alveoli of the lungs lose their elasticity and the walls between adjacent alveoli are destroyed. As more and more alveoli walls are lost, the air exchange surface area of the lungs is reduced until air exchange becomes seriously impaired. The combination of mucus hypersecretion and dynamic air compression is a mechanism of airflow limitation in chronic obstructive pulmonary disease. Dynamic air compression results from the loss of tethering forces exerted on the airway due to the reduction in lung tissue elasticity. Essentially, stale air accumulates in the lungs, thereby depriving the individual of oxygen. Various methods may be utilized to determine the location or locations of the diseased tissue, for example, computerized axial tomography or CAT scans, magnetic resonance imaging or MRI, positron emission tomograph or PET, and/or standard X-ray imaging. Once the location or locations of the diseased tissue are located, anastomotic openings are made in the thoracic cavity and lung or lungs and one or more oxygen carrying conduits are positioned and sealed therein. The one or more oxygen carrying conduits are connected to an oxygen source which supplies oxygen under elevated pressure directly to the diseased portion or portions of the lung or lungs. The pressurized oxygen essentially displaces the accumulated air and is thus more easily absorbed by the alveoli tissue. In addition, the long term oxygen therapy system may be configured in such a way as to provide collateral ventilation bypass in addition to direct oxygen therapy. In this configuration, an additional conduit may be connected between the main conduit and the individual's trachea with the appropriate valve arrangement. In this configuration, stale air may be removed through the trachea when the individual exhales since the trachea is directly linked with the diseased site or sites in the lung via the conduits.
The long term oxygen therapy system of the present invention improves oxygen transfer efficiency in the lungs thereby reducing oxygen supply requirements, which in turn reduces the patient's medical costs. The system also allows for improved self-image, improved mobility, greater exercise capability and is easily maintained.
The above-described long term oxygen therapy system may be utilized to effectively treat hypoxia caused by chronic obstructive pulmonary disease; however, other means may be desirable to treat other aspects of the disease. As set forth above, emphysema is distinguished as irreversible damage to lung tissue. The breakdown of lung tissue leads to the reduced ability for the lungs to recoil. The tissue breakdown also leads to the loss of radial support of the airways. Consequently, the loss of elastic recoil of the lung tissue contributes to the inability for individuals with emphysema to exhale completely. The loss of radial support of the airways also allows a collapsing phenomenon to occur during the expiratory phase of breathing. This collapsing phenomenon also intensifies the inability for individuals to exhale completely. As the inability to exhale increases, residual volume in the lungs also increases. This then causes the lung to establish in a hyperinflated state wherein an individual can only take short shallow breaths.
The collateral ventilation bypass trap system of the present invention utilizes the above-described collateral ventilation phenomenon to increase the expiratory flow from a diseased lung or lungs, thereby treating another aspect of chronic obstructive pulmonary disease. Essentially, the most collaterally ventilated area of the lung or lungs is determined utilizing the scanning techniques described above. Once this area or areas are located, a conduit or conduits are positioned in a passage or passages that access the outer pleural layer of the diseased lung or lungs. The conduit or conduits utilize the collateral ventilation of the lung or lungs and allow the entrapped air to bypass the native airways and be expelled to a containment system outside of the body.
In an alternate embodiment, the trachea, or other proximal airways, including the bronchus, may be utilized for expelling trapped air rather than a containment/trap device.
The pulmonary decompression device of the present invention removes air from hyperinflated regions of the lung or lungs of a patient by creating a slight pressure differential between the internal volume of the lung and a location external of the lung. An apparatus such as a vacuum fan or pump creates the pressure differential, thereby removing the trapped air and reducing the volume of diseased tissue.
In order for the system to be effective, the components of the system are preferably sealed to the lung. Accordingly, the localized pleurodesis chemical delivery system of the present invention is utilized to create a pleurodesis in the area or areas of the lung that are most collaterally ventilated. Various chemicals, agents and/or compounds may be delivered via catheter based delivery systems or via implantable medical devices.
The foregoing and other features and advantages of the invention will be apparent from the following, more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings.
a and 12b are diagrammatic representations of the effects on lung volume in accordance with the present invention.
Air typically enters the mammalian body through the nostrils and flows into the nasal cavities. As the air passes through the nostrils and nasal cavities, it is filtered, moistened and raised or lowered to approximately body temperature. The back of the nasal cavities is continuous with the pharynx (throat region); therefore, air may reach the pharynx from the nasal cavities or from the mouth. Accordingly, if equipped, the mammal may breath through its nose or mouth. Generally air from the mouth is not as filtered or temperature regulated as air from the nostrils. The air in the pharynx flows from an opening in the floor of the pharynx and into the larynx (voice box). The epiglottis automatically closes off the larynx during swallowing so that solids and/or liquids enter the esophagus rather than the lower air passageways or airways. From the larynx, the air passes into the trachea, which divides into two branches, referred to as the bronchi. The bronchi are connected to the lungs.
The lungs are large, paired, spongy, elastic organs, which are positioned in the thoracic cavity. The lungs are in contact with the walls of the thoracic cavity. In humans, the right lung comprises three lobes and the left lung comprises two lobes. Lungs are paired in all mammals, but the number of lobes or sections of lungs varies from mammal to mammal. Healthy lungs, as discussed below, have a tremendous surface area for gas/air exchange. Both the left and right lung is covered with a pleural membrane. Essentially, the pleural membrane around each lung forms a continuous sac that encloses the lung. A pleural membrane also forms a lining for the thoracic cavity. The space between the pleural membrane forming the lining of the thoracic cavity and the pleural membranes enclosing the lungs is referred to as the pleural cavity. The pleural cavity comprises a film of fluid that serves as a lubricant between the lungs and the chest wall.
In the lungs, the bronchi branch into a multiplicity of smaller vessels referred to as bronchioles. Typically, there are more than one million bronchioles in each lung. Each bronchiole ends in a cluster of extremely small air sacs referred to as alveoli. An extremely thin, single layer of epithelial cells lining each alveolus wall and an extremely thin, single layer of epithelial cells lining the capillary walls separate the air/gas in the alveolus from the blood. Oxygen molecules in higher concentration pass by simple diffusion through the two thin layers from the alveoli into the blood in the pulmonary capillaries. Simultaneously, carbon dioxide molecules in higher concentration pass by simple diffusion through the two thin layers from the blood in the pulmonary capillaries into the alveoli.
Breathing is a mechanical process involving inspiration and expiration. The thoracic cavity is normally a closed system and air cannot enter or leave the lungs except through the trachea. If the chest wall is somehow compromised and air/gas enters the pleural cavity, the lungs will typically collapse. When the volume of the thoracic cavity is increased by the contraction of the diaphragm, the volume of the lungs is also increased. As the volume of the lungs increase, the pressure of the air in the lungs falls slightly below the pressure of the air external to the body (ambient air pressure). Accordingly, as a result of this slight pressure differential, external or ambient air flows through the respiratory passageways described above and fills the lungs until the pressure equalizes. This process is inspiration. When the diaphragm is relaxed, the volume of the thoracic cavity decreases, which in turn decreases the volume of the lungs. As the volume of the lungs decrease, the pressure of the air in the lungs rises slightly above the pressure of the air external to the body. Accordingly, as a result of this slight pressure differential, the air in the alveoli is expelled through the respiratory passageways until the pressure equalizes. This process is expiration.
Continued insult to the respiratory system may result in various diseases, for example, chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease is a persistent obstruction of the airways caused by chronic bronchitis and pulmonary emphysema. In the United States alone, approximately fourteen million people suffer from some form of chronic obstructive pulmonary disease and it is in the top ten leading causes of death.
Chronic bronchitis and acute bronchitis share certain similar characteristics; however, they are distinct diseases. Both chronic and acute bronchitis involve inflammation and constriction of the bronchial tubes and the bronchioles; however, acute bronchitis is generally associated with a viral and/or bacterial infection and its duration is typically much shorter than chronic bronchitis. In chronic bronchitis, the bronchial tubes secrete too much mucus as part of the body's defensive mechanisms to inhaled foreign substances. Mucus membranes comprising ciliated cells (hair like structures) line the trachea and bronchi. The ciliated cells or cilia continuously push or sweep the mucus secreted from the mucus membranes in a direction away from the lungs and into the pharynx, where it is periodically swallowed. This sweeping action of the cilia functions to keep foreign matter from reaching the lungs. Foreign matter that is not filtered by the nose and larynx, as described above, becomes trapped in the mucus and is propelled by the cilia into the pharynx. When too much mucus is secreted, the ciliated cells may become damaged, leading to a decrease in the efficiency of the cilia to sweep the bronchial tubes and trachea of the mucus containing the foreign matter. This in turn causes the bronchioles to become constricted and inflamed and the individual becomes short of breath. In addition, the individual will develop a chronic cough as a means of attempting to clear the airways of excess mucus.
Individuals who suffer from chronic bronchitis may develop pulmonary emphysema. Pulmonary emphysema is a disease in which the alveoli walls, which are normally fairly rigid structures, are destroyed. The destruction of the alveoli walls is irreversible. Pulmonary emphysema may be caused by a number of factors, including chronic bronchitis, long term exposure to inhaled irritants, e.g. air pollution, which damage the cilia, enzyme deficiencies and other pathological conditions. In pulmonary emphysema, the alveoli of the lungs lose their elasticity, and eventually the walls between adjacent alveoli are destroyed. Accordingly, as more and more alveoli walls are lost, the air exchange (oxygen and carbon dioxide) surface area of the lungs is reduced until air exchange becomes seriously impaired. The combination of mucus hypersecretion and dynamic airway compression are mechanisms of airflow limitation in chronic obstructive pulmonary disease. Dynamic airway compression results from the loss of tethering forces exerted on the airway due to the reduction in lung tissue elasticity. Mucus hypersecretion is described above with respect to bronchitis. In other words, the breakdown of lung tissue leads to the reduced ability of the lungs to recoil and the loss of radial support of the airways. Consequently, the loss of elastic recoil of the lung tissue contributes to the inability of individuals to exhale completely. The loss of radial support of the airways also allows a collapsing phenomenon to occur during the expiratory phase of breathing. This collapsing phenomenon also intensifies the inability for individuals to exhale completely. As the inability to exhale completely increases, residual volume in the lungs also increases. This then causes the lung to establish in a hyperinflated state where an individual can only take short shallow breaths. Essentially, air is not effectively expelled and stale air accumulates in the lungs. Once the stale air accumulates in the lungs, the individual is deprived of oxygen. There is no cure for pulmonary emphysema, only various treatments, including exercise, drug therapy, such as bronchodilating agents, lung volume reduction surgery and long term oxygen therapy.
As described above, long term oxygen therapy is widely accepted as the standard treatment for hypoxia caused by chronic obstructive pulmonary disease. Typically, oxygen therapy is prescribed using a nasal cannula. There are disadvantages associated with using the nasal cannula. One disadvantage associated with utilizing nasal cannula is the significant loss of oxygen between the cannula and the nose, which in turn equates to more frequent changes in the oxygen source, or higher energy requirements to generate more oxygen. Another disadvantage associated with utilizing nasal cannula is the fact that the cannulas may cause the nasal passages to become dry, cracked and sore.
Transtracheal oxygen therapy has become a viable alternative to long term oxygen therapy. Transtracheal oxygen therapy delivers oxygen directly to the lungs using a catheter that is placed through and down the trachea. Due to the direct nature of the oxygen delivery, a number of advantages are achieved. These advantages include lower oxygen requirements due to greater efficiency, increased mobility, greater exercise capability and improved self image.
The long term oxygen therapy system and method of the present invention may be utilized to deliver oxygen directly into the lung tissue in order to optimize oxygen transfer efficiency in the lungs. In other words, improved efficiency may be achieved if oxygen were to be delivered directly into the alveolar tissue in the lungs. In emphysema, alveoli walls are destroyed, thereby causing a decrease in air exchange surface area. As more alveoli walls are destroyed, collateral ventilation resistance is lowered. In other words, pulmonary emphysema causes an increase in collateral ventilation and to a certain extent, chronic bronchitis also causes an increase in collateral ventilation. Essentially, in an emphysematous lung, the communicating flow of air between neighboring air sacs (alveoli), known as collateral ventilation, is much more prevalent as compared to a normal lung. Since air cannot be expelled from the native airways due to the loss of tissue elastic recoil and radial support of the airways (dynamic collapse during exhalation), the increase in collateral ventilation does not significantly assist an individual in breathing. The individual develops dsypnea. Accordingly, if it can be determined where collateral ventilation is occurring, then the diseased lung tissue may be isolated and the oxygen delivered to this precise location or locations. Various methods may be utilized to determine the diseased tissue locations, for example, computerized axial tomography or CAT scans, magnetic resonance imaging or MRI, positron emission tomograph or PET, and/or standard X-ray imaging. Once the diseased tissue is located, pressurized oxygen may be directly delivered to these diseased areas and more effectively and efficiently forced into the lung tissue for air exchange.
The exemplary system 100 described above may be modified in a number of ways, including the use of an in-line filter. In this exemplary embodiment, both oxygen and air may flow through the system. In other words, during inhalation, oxygen is delivered to the lungs through the oxygen carrying conduit 104 and during exhalation, air from the lungs flow through the oxygen carrying conduit 104. The in-line filter would trap mucus and other contaminants, thereby preventing a blockage in the oxygen source 102. In this exemplary embodiment, no valve 106 would be utilized. The flow of oxygen into the lungs and the flow of air from the lungs is based on pressure differentials.
In order for the exemplary long term oxygen therapy system 100 to function, an airtight seal is preferably maintained where the oxygen carrying conduit 104 passes through the thoracic cavity and lung. This seal is maintained in order to sustain the inflation/functionality of the lungs. If the seal is breached, air can enter the cavity and cause the lungs to collapse as described above.
A method to create this seal comprises forming adhesions between the visceral pleura of the lung and the inner wall of the thoracic cavity. This may be achieved using either chemical methods, including irritants such as Doxycycline and/or Bleomycin, surgical methods, including pleurectomy or horoscope talc pleurodesis, or radiotherapy methods, including radioactive gold or external radiation. All of these methods are known in the relevant art for creating pleurodesis. With a seal created at the site for the ventilation bypass, an intervention may be safely performed without the danger of creating a pneumothorax of the lung.
Similarly to ostomy pouches or bags, the oxygen carrying conduit 104 may be sealed to the skin at the site of the ventilation bypass. In one exemplary embodiment, illustrated in
If an individual has difficulty exhaling and requires additional oxygen, collateral ventilation bypass may be combined with direct oxygen therapy.
The connection and sealing of the oxygen carrying conduit 604 and branches 606, 608 to the lung 612 and bronchial tube 614 may be made in a manner similar to that described above.
The above-described long term oxygen therapy system may be utilized to effectively treat hypoxia caused by chronic obstructive pulmonary disease; however, other means may be desirable to treat other aspects of the disease. As set forth above, emphysema is distinguished as irreversible damage to lung tissue. The breakdown of lung tissue leads to the reduced ability for the lungs to recoil. The tissue breakdown also leads to the loss of radial support of the native airways. Consequently, the loss of elastic recoil of the lung tissue contributes to the inability for individuals with emphysema to exhale completely. The loss of radial support of the native airways also allows a collapsing phenomenon to occur during the expiratory phase of breathing. This collapsing phenomenon also intensifies the inability for individuals to exhale completely. As the inability to exhale increases, residual volume in the lungs also increases. This then causes the lung to establish in a hyperinflated state wherein an individual can only take short shallow breaths.
The collateral ventilation bypass trap system of the present invention utilizes the above-described collateral ventilation phenomenon to increase the expiratory flow from a diseased lung or lungs, thereby treating another aspect of chronic obstructive pulmonary disease. Essentially, the most collaterally ventilated area of the lung or lungs is determined utilizing the scanning techniques described above. Once this area or areas are located, a conduit or conduits are positioned in a passage or passages that access the outer pleural layer of the diseased lung or lungs. The conduit or conduits utilize the collateral ventilation of the lung or lungs and allows the entrapped air to bypass the native airways and be expelled to a containment system outside of the body.
The trap 702 may comprise any suitable device for collecting discharge from the individual's lung or lungs 708. Essentially, the trap 702 is simply a containment vessel for temporarily storing discharge from the lungs, for example, mucous and other fluids that may accumulate in the lungs. The trap 702 may comprise any suitable shape and may be formed from any suitable metallic or non-metallic materials. Preferably, the trap 702 should be formed from a lightweight, non-corrosive material. In addition, the trap 702 should be designed in such a manner as to allow for effective and efficient cleaning. In one exemplary embodiment, the trap 702 may comprise disposable liners that may be removed when the trap 702 is full. The trap 702 may be formed from a transparent material or comprise an indicator window so that it may be easily determined when the trap 702 should be emptied or cleaned. A lightweight trap 702 increases the patient's mobility.
The filter/one-way valve 706 may be attached to the trap 702 by any suitable means, including threaded fittings or compression type fittings commonly utilized in compressor connections. The filter/one-way valve 706 serves a number of functions. The filter/one-way valve 706 allows the air from the individual's lung or lungs 708 to exit the trap 702 while maintaining the fluid discharge and solid particulate matter in the trap 702. This filter/one-way valve 706 would essentially maintain the pressure in the trap 702 below that of the pressure inside the individual's lung or lungs 708 so that the flow of air from the lungs 708 to the trap 702 is maintained in this one direction. The filter portion of the filter/one-way valve 706 may be designed to capture particulate matter of a particular size which is suspended in the air, but allows the clean air to pass therethrough and be vented to the ambient environment. The filter portion may also be designed in such a manner as to reduce the moisture content of the exhaled air.
The air carrying conduit 704 connects the trap 702 to the lung or lungs 708 of the patient through the filter/one-way valve 706. The air carrying conduit 704 may comprise any suitable biocompatible tubing having a resistance to the gases contained in air. The air carrying conduit 704 comprises tubing having an inside diameter in the range from about 1/16 inch to about ½ inch, and more preferably from about ⅛ inch to about ¼ inch. The filter/one-way valve 706 may comprise any suitable valve which allows air to flow from the lung or lungs 708 through the air carrying conduit 704, but not from the trap 702 back to the lungs 708. For example, a simple check valve may be utilized. The air carrying conduit 704 may be connected to the filter/one-way valve 706 by any suitable means. Preferably, a quick release mechanism is utilized so that the trap may be easily removed for maintenance.
As illustrated in
The air carrying conduit 704 is preferably able to withstand and resist collapsing once in place. Since air will travel through the conduit 704, if the conduit is crushed and unable to recover, the effectiveness of the system is diminished. Accordingly, a crush recoverable material may be incorporated into the air carrying conduit 704 in order to make it crush recoverable. Any number of suitable materials may be utilized. For example, Nitinol incorporated into the conduit 704 will give the conduit collapse resistance and collapse recovery properties.
Expandable features at the end of the conduit 704 may be used to aid in maintaining contact and sealing the conduit 704 to the lung pleura. Nitinol incorporated into the conduit 704 will provide the ability to deliver the conduit 704 in a compressed state and then deployed in an expanded state to secure it in place. Shoulders at the end of the conduit may also provide a mechanical stop for insertion and an area for an adhesive/sealant to join as described in detail subsequently.
In order for the exemplary collateral ventilation bypass trap system 700 to function, an airtight seal is preferably maintained where the air carrying conduit 704 passes through the thoracic cavity and lungs 708. This seal is maintained in order to sustain the inflation/functionality of the lungs. If the seal is breached, air can enter the cavity and cause the lungs to collapse. One exemplary method for creating the seal comprises forming adhesions between the visceral pleura of the lung and the inner wall of the thoracic cavity. This may be achieved using either chemical methods, including irritants such as Doxycycline and/or Bleomycin, surgical methods, including pleurectomy or thorascopic talc pleurodesis, or radiotherapy methods, including radioactive gold or external radiation. All of these methods are known in the relevant art for creating pleurodesis. In another alternate exemplary embodiment, a sealed joint between the air carrying conduit 704 and the outer pleural layer includes using various glues to help with the adhesion/sealing of the air carrying conduit 704. Currently, Focal Inc. markets a sealant available under the tradename Focal/Seal-L which is indicated for use on a lung for sealing purposes. Focal/Seal-L is activated by light in order to cure the sealant. Another seal available under the tradename Thorex, which is manufactured by Surgical Sealants Inc., is currently conducting a clinical trial for lung sealing indications. Thorex is a two-part sealant that has a set curing time after the two parts are mixed.
The creation of the opening in the chest cavity may be accomplished in a number of ways. For example, the procedure may be accomplished using an open chest procedure, aternotomy or thoracotomy. Alternately, the procedure may be accomplished using a laproscopic technique, which is less invasive. Regardless of the procedure utilized, the seal should be established while the lung is at least partially inflated in order to maintain a solid adhesive surface. The opening may then be made after the joint has been adequately created between the conduit component and the lung pleural surface. The opening should be adequate in cross-sectional area in order to provide sufficient decompression of the hyperinflated lung. This opening, as stated above, may be created using a number of different techniques such as cutting, piercing, dilating, blunt dissection, radio frequency energy, ultrasonic energy, microwave energy, or cryoblative energy.
The air carrying conduit 704 may be sealed to the skin at the site by any of the means and methods described above with respect to the oxygen carrying conduit 704 and illustrated in
In operation, when an individual exhales, the pressure in the lungs is greater than the pressure in the trap 702. Accordingly, the air in the highly collaterilized areas of the lung will travel through the air carrying conduit 704 to the trap 702. This operation will allow the individual to more easily and completely exhale.
The first and second conduits 802, 806 may comprise any suitable biocompatible tubing having a resistance to the various gases and other constituents contained in inhaled and exhaled air. As in previously described embodiments, the first and second conduits 802, 806 comprise tubing having an inside diameter in the range from about 1/16 inch to about ½ inch, and more preferably from about ⅛ inch to about ¼ inch.
The connection of the first conduit 802 to the trachea 804 may comprise any suitable airtight seal. For example, a fluid communication between the trachea 804 and the first conduit 802 may be established in a manner identical to that established for a tracheotomy. In addition, as stated above, in order for the collateral ventilation bypass system 800 to function, an airtight seal is preferably maintained where the second conduit 806 passes through the thoracic wall 810 and into the lungs 812. An exemplary method for creating this airtight seal comprises forming adhesions between the visceral pleura of the lung and the parietal pleura. This may be achieved using either chemical methods, including irritants, surgical methods, including pleurectomy or thorascopic talc pleurodesis, or radiotherapy methods, including radioactive gold or external radiation.
The creation of the opening in the thoracic wall may be accomplished in a number of ways. For example, the procedure may be accomplished using an open chest procedure, aternotomy or thoracotomy. Alternately, the procedure may be accomplished using a laproscopic technique, which is less invasive. Regardless of the procedure utilized, the seal should be established while the lung is at least partially inflated in order to maintain a solid adhesive surface. The opening may then be made after the joint has been adequately created between the conduit component and the lung pleural surface. The opening should be adequate in cross-sectional area in order to provide sufficient decompression of the hyperinflated lung. This opening, as stated above, may be created using a number of different techniques such as cutting, piercing, dilating, blunt dissection, radio frequency energy, ultrasonic energy, microwave energy, or cryoblative energy.
The conduits 802, 806 may be sealed to the skin at the sites by any known methods, including those described above with respect to
The fitting 808 connecting the first and second conduits 802, 806 may comprise any suitable device for creating an airtight seal. The fitting 808 may comprise any type of threaded or non-threaded union, compression fittings similar to compressor type fittings or any other suitable device for establishing an airtight seal and providing for quick release between the two ends of the fitting 808. This type of design would allow easy access for periodic maintenance of the system 800, for example, cleaning the conduits 802, 806. Since the fitting 808 is external to the body, access to the inner body component of the system 800 would be easier. Essentially, access of the system 800 from outside the body would allow for maintenance and diagnosis/observation of the system 800 without subjecting the patient to additional stress and risk. It would also be less time consuming for the doctor.
The access port 908 may comprise any suitable device for providing an airtight seal when closed and easy access to the conduit 902 when open. The access port 908 may comprise various valve arrangements and connectors for connecting other components which may be utilized for various functions. For example, oxygen may be supplied directly to the patient's lungs 912 if needed. In this instance, a valve may be needed to prevent the oxygen from bypassing the lungs 912 and go straight to the trachea 904.
All the remaining components may be the same as described above. In addition, all seals may be accomplished as described above.
In yet another alternate exemplary embodiment, the extrathoracic access port 908, illustrated in
As illustrated in
It is important to note that in each of the above-described exemplary embodiments, additional components may be added that function to prevent flow from the trachea end of the conduit to the lung. For example, one or more valves may be incorporated throughout the systems to prevent mucus and other substances from entering or re-entering the lung. The main function of the system is to allow exhalation. In theory, patients with emphysema have increased resistance to expiration and not inhalation. Any suitable valves may be utilized, for example, one-way check valves.
As described above, pulmonary emphysema leads to the breakdown of lung tissue, which in turn leads to the reduced ability of the lungs to recoil and the loss of radial support of the airways. Consequently, the loss of elastic recoil of the lung tissue contributes to the inability of individuals to exhale completely. The loss of radial support of the airways also allows a collapsing phenomenon to occur during the expiratory phase of breathing. This collapsing phenomenon also intensifies the inability for individuals to exhale completely. As the inability to exhale completely increases, residual volume in the lungs also increases. This then causes the lung or lungs to establish in a hyperinflated state where an individual can only take short shallow breaths. Essentially, air is not effectively expelled and stale air accumulates in the lungs. Once the stale air accumulates in the lungs, the individual is deprived of oxygen.
Lung volume reduction surgery is an extremely traumatic procedure that involves removing part or parts of the lung or lungs. By removing the portion of the lung or lungs which is hyperinflated, pulmonary function may improve due to a number of mechanisms, including enhanced elastic recoil, correction of ventilation/perfusion mismatch and improved efficiency of respiratory work. Essentially, as the emphysematous tissue volume is reduced, the healthier tissue is better ventilated. However, lung volume reduction surgery possesses a number of potential risks as described in more detail subsequently.
The collateral ventilation bypass trap system 700, illustrated in
The exemplary pulmonary decompression assist device of the present invention may be strategically positioned in the body of a patient such that it is in fluid communication with the patient's lung or lungs and the external environment. The device would allow air to be exhaled out from the lung or lungs through the native airways while assisting in removing trapped air in the hyperinflated portion of the lung or lungs. Lung volume reduction surgery is an extremely invasive and traumatic procedure that in a substantially high number of cases causes the patients undergoing the procedure to become excluded from being a candidate for lung transplantation. The device of the present invention provides for a minimally invasive procedure for causing the lung volume to reduce similarly to lung volume reduction surgery while allowing the patient to remain a viable candidate for lung transplantation.
The exemplary pulmonary decompression device may utilize any number of known techniques for creating a sufficient pressure differential between the inside of the lung or lungs and an area external of the lung or lungs to allow the trapped air to exit the lung or lungs. The device may comprise any suitable device such as pumps or fans or any other means to create the pressure differential. If the collateral airflow and areas of emphysema are situated so that air may reinflate that area, the device may be configured to continuously draw air from the lung or lungs to maintain a smaller lung volume of the emphysematous tissue. The device may be left in the patient's body indefinitely in order to maintain the compression of the emphysematous tissue in the lung or lungs. In addition, in order to maintain the cleanliness of the device and the safety of the patient, the device may be constructed as a disposable device and be replaced at various intervals. In addition, portions of the device that are easily accessible may be made disposable. Alternately, the device may be constructed for easy removal, easy cleaning and easy replacement.
Referring to
It is important to note that one or more devices may be utilized in each lung to remove trapped air from highly collateralized areas. Alternately, a single device with multiple conduits may be utilized. As illustrated in
At least a portion of the second section 1108 is external to the patient's body. The portion of the second section 1108 that is external to the patient's body may exit the body at any suitable location. In one exemplary embodiment, the portion of the second section 1108 exits the body through the chest and thus may be sealed in accordance with any of the devices and methodologies described herein.
The first section 1106 may comprise any suitable biocompatible material configured to facilitate the flow of air from the lung 1102. For example, the first section 1106 may comprise a conduit similar in size, material and construction as the other conduits described herein. The second section 1108 may be connected to the first section 1106 by any suitable means, including threaded unions or compression type fittings. The second section 1108 comprises a housing for an apparatus 1110 that draws air from the hyperinflated portion of the lung 1104 through the first section 1106 and directs it out of the patient's body. The apparatus 1110 may include any suitable device for creating a pressure differential between the inside and outside of the lung 1102 such that air will easily flow from the lung 1102. The apparatus 1110 may include a miniature pump or fan. The miniature pump or fan may be powered by any suitable means, including batteries or rechargeable batteries. In the above-described exemplary embodiment, the miniature pump or fan and its power supply 1112 may be housed completely in the housing. In other alternate exemplary embodiments, one or more of the pump/fan or power supply 1112 may be located remotely from the second section 1108. For example, the second section 1108 may simply comprise a second conduit removably connected on one end to the first conduit and on a second end to the apparatus 1110 that draws air from the diseased section of the lung 1104.
In the exemplary embodiment illustrated in
The power supply 1112 may comprise any suitable means for supplying power continuously for extended periods of time. The power supply 1112 may comprise batteries, rechargeable batteries, piezoelectric devices that generate electrical power from mechanical strain or any other suitable device. In addition, other than a fan or pump for creating a vacuum, some type of switching elements may be utilized for creating a slight pressure differential.
Accordingly, rather than a resection of the lung tissue, the decompression device removes trapped air from the emphysematous section of the lung and maintains the emphysematous section in a compressed state or smaller volume, thereby allowing the healthier lung tissue more volume in the thoracic cavity to ventilate.
In the above-described exemplary apparatus and procedure for increasing expiratory flow from a diseased lung using the phenomenon of collateral ventilation, there will be an optimal location to penetrate the outer pleura of the lung to access the most collaterally ventilated area or areas of the lung. In addition, in the above-described exemplary pulmonary decompression assist device, there is an optimal location for decompressing the hyperinflated lung or lungs. As described above, there are a variety of techniques to locate the most collaterally ventilated area or areas of the lungs. Since a device or component of the apparatus functions to allow the air entrapped in the lung to bypass the native airways and be expelled outside of the body, it is particularly advantageous to provide an airtight seal 1114 of the parietal 1117 (thoracic wall) and visceral 1116 (lung) pleurae. If a proper airtight seal 1114 is not created between the device, parietal 1117 and visceral 1116 pleurae, then a pneumothorax (collapsed lung) may occur. Essentially, in any circumstance where the lung is punctured and a device inserted, an airtight seal 1114 should preferably be maintained.
One way to achieve an airtight seal 1114 is through pleurodesis, i.e. an obliteration of the pleural space 1118. There are a number of pleurodesis methods, including chemical, surgical and radiological. In chemical pleurodesis, an agent such as tetracycline, doxycycline, bleomycin or nitrogen mustard may be utilized. In surgical pleurodesis, a pleurectomy or a thorascopic talc procedure may be performed. In radiological procedures, radioactive gold or external radiation may be utilized. In the present invention, chemical pleurodesis is utilized.
Exemplary devices and methods for delivering a chemical(s) or agent(s) in a localized manner for ensuring a proper airtight seal 1114 of the above-described apparatus is described below. The chemical(s), agent(s) and/or compound(s) are used to create a pleurodesis between the parietal 1117 and visceral 1116 pleura so that a component of the apparatus may penetrate through the particular area and not result in a pneumothorax. There are a number of chemical(s), agent(s) and/or compound(s) that may be utilized to create a pleurodesis in the pleural space 1118. The chemical(s), agent(s) and/or compound(s) include talc, tetracycline, doxycycline, bleomycin and minocycline.
In one exemplary embodiment, a modified drug delivery catheter may be utilized to deliver chemical(s), agent(s) and/or compound(s) to a localized area for creating a pleurodesis in that area. In this exemplary embodiment, the pleurodesis is formed and then the conduit 704, as illustrated in
As illustrated in
The distal end or tip 1302 of the catheter 1300 should preferably maintain its desired size, shape and/or configuration once deployed in the pleural space. This may be accomplished in a number of ways. For example, the material forming the distal end 1302 of the catheter 1300 may be selected such that it has a certain degree of flexibility for insertion of the catheter 800 and a certain degree of shape memory such that it resumes its original or programmed shape once deployed. Any number of biocompatible polymers with these properties may be utilized. In an alternate embodiment, another material may be utilized. For example, a metallic material having shape memory characteristics may be integrated into the distal end 1302 of the catheter 1300. This metallic material may include nitinol or stainless steel. In addition, the metallic material may be radiopaque or comprise radiopaque markers. By having a radiopaque material or radiopaque markers, the catheter 1300 may be viewed under x-ray fluoroscopy and aid in determining when the catheter 1300 is at the location of the highest collateral ventilation.
In another alternate exemplary embodiment, a local drug delivery device may be utilized to deliver the pleurodesis chemical(s), agent(s) and/or compound(s). In this exemplary embodiment, the pleurodesis is formed and then the conduit 704, as illustrated in
Any of the above-described chemical(s), agent(s) and/or compound(s) may be affixed to the medical device. The chemical(s), agent(s) and/or compound(s) may be affixed to the medical device in any suitable manner. For example, the chemical(s), agent(s) and/or compound(s) may be coated on the device utilizing any number of well known techniques including, spin coating, spraying or dipping, they may be incorporated into a polymeric matrix that is affixed to the surface of the medical device, they may be impregnated into the outer surface of the medical device, they may be incorporated into holes or chambers in the medical device, they may be coated onto the surface of the medical device and then coated with a polymeric layer that acts as a diffusion barrier for controlled release of the chemical(s), agent(s) and/or compound(s), they may be incorporated directly into the material forming the medical device, or any combination of the above-described techniques. In another alternate embodiment, the medical device may be formed from a biodegradable material which elutes the chemical(s), agent(s) and/or compound(s) as the device degrades.
The implantable medical device may comprise any suitable size, shape and/or configuration, and may be formed using any suitable biocompatible material.
As described in the previous exemplary embodiment, the disk 1400 may comprise a radiopaque marker or be formed from a radiopaque material. The radiopaque marker or material allows the disk 1400 to be seen under fluoroscopy and then positioned accurately.
In yet another alternate exemplary embodiment, the fluid characteristics of the chemical(s), agent(s) and/or compound(s) may be altered. For example, the chemical(s), agent(s) and/or compound(s) may be made more viscous. With a more viscous chemical agent and/or compound, there would be less chance of the chemical, agent and/or compound moving from the desired location in the pleural space. The chemical(s), agent(s) and/or compound(s) may also comprise radiopaque constituents. Making the chemical(s), agent(s) and/or compounds radiopaque would allow the confirmation of the location of the chemical(s), agent(s) and/or compound(s) with regard to the optimal location of collateral ventilation.
The chemical(s), agent(s) and/or compound(s) as modified above may be utilized in conjunction with standard chemical pleurodesis devices and processes or in conjunction with the exemplary embodiments set forth above.
Although shown and described is what is believed to be the most practical and preferred embodiments, it is apparent that departures from specific designs and methods described and shown will suggest themselves to those skilled in the art and may be used without departing from the spirit and scope of the invention. The present invention is not restricted to the particular constructions described and illustrated, but should be constructed to cohere with all modifications that may fall within the scope of the appended claims.
This application claims the benefit of Provisional Application No. 60/473,999 filed May 29, 2003.
| Number | Name | Date | Kind |
|---|---|---|---|
| 733152 | Chisholm | Jul 1903 | A |
| 953922 | Rogers | Apr 1910 | A |
| 2206687 | Bloomheart | Jul 1940 | A |
| 2867213 | Thomas, Jr. | Jan 1959 | A |
| 2873742 | Shelden | Feb 1959 | A |
| 2991787 | Shelden et al. | Jul 1961 | A |
| 3253594 | Matthews et al. | May 1966 | A |
| 3384087 | Brummelkamp | May 1968 | A |
| 3463159 | Heimlich | Aug 1969 | A |
| 3511243 | Toy | May 1970 | A |
| 3556103 | Calhoun | Jan 1971 | A |
| 3638649 | Ersek | Feb 1972 | A |
| 3682166 | Jacobs | Aug 1972 | A |
| 3688773 | Weiss | Sep 1972 | A |
| 3777757 | Gray et al. | Dec 1973 | A |
| 3788326 | Jacobs | Jan 1974 | A |
| 3817250 | Weiss et al. | Jun 1974 | A |
| 3908704 | Clement et al. | Sep 1975 | A |
| 3916903 | Pozzi | Nov 1975 | A |
| 4153058 | Nehme | May 1979 | A |
| 4291694 | Chai | Sep 1981 | A |
| 4439189 | Sargeant et al. | Mar 1984 | A |
| 4465062 | Versaggi et al. | Aug 1984 | A |
| 4502482 | DeLuccia et al. | Mar 1985 | A |
| 4583977 | Shishov et al. | Apr 1986 | A |
| 4664660 | Goldberg et al. | May 1987 | A |
| 4799494 | Wang | Jan 1989 | A |
| 4813929 | Semrad | Mar 1989 | A |
| 4826495 | Petersen | May 1989 | A |
| 4828553 | Nielsen | May 1989 | A |
| 4857063 | Glenn | Aug 1989 | A |
| 4869717 | Adair | Sep 1989 | A |
| 4872869 | Johns | Oct 1989 | A |
| 4889534 | Mohiuddin et al. | Dec 1989 | A |
| 4931045 | Steer | Jun 1990 | A |
| 4944724 | Goldberg et al. | Jul 1990 | A |
| 4959054 | Heimke et al. | Sep 1990 | A |
| 4976688 | Rosenblum | Dec 1990 | A |
| 4986839 | Wertz et al. | Jan 1991 | A |
| 5004456 | Botterbusch et al. | Apr 1991 | A |
| 5060645 | Russell | Oct 1991 | A |
| 5078689 | Keller | Jan 1992 | A |
| 5137509 | Freitas | Aug 1992 | A |
| 5139485 | Smith et al. | Aug 1992 | A |
| 5218957 | Strickland | Jun 1993 | A |
| 5230332 | Strickland | Jul 1993 | A |
| 5230350 | Fentress | Jul 1993 | A |
| 5261708 | Steer | Nov 1993 | A |
| 5263939 | Wortrich | Nov 1993 | A |
| 5312331 | Knoepfler | May 1994 | A |
| 5315992 | Dalton | May 1994 | A |
| 5318517 | Reiman | Jun 1994 | A |
| 5336206 | Shichman | Aug 1994 | A |
| 5354283 | Bark et al. | Oct 1994 | A |
| 5356386 | Goldberg et al. | Oct 1994 | A |
| 5366478 | Brinkerhoff et al. | Nov 1994 | A |
| 5370625 | Shichman | Dec 1994 | A |
| 5376376 | Li | Dec 1994 | A |
| 5389077 | Melinyshyn et al. | Feb 1995 | A |
| 5401262 | Karwoski et al. | Mar 1995 | A |
| 5431633 | Fury | Jul 1995 | A |
| 5478333 | Asherman, Jr. | Dec 1995 | A |
| 5484401 | Rodriguez et al. | Jan 1996 | A |
| 5496297 | Olsen | Mar 1996 | A |
| 5501677 | Jensen | Mar 1996 | A |
| 5501678 | Olsen | Mar 1996 | A |
| 5562608 | Sekins et al. | Oct 1996 | A |
| 5588424 | Insler et al. | Dec 1996 | A |
| 5616131 | Sauer et al. | Apr 1997 | A |
| 5645565 | Rudd et al. | Jul 1997 | A |
| 5660175 | Dayal | Aug 1997 | A |
| 5662629 | Steer et al. | Sep 1997 | A |
| 5728066 | Daneshvar | Mar 1998 | A |
| 5730735 | Holmberg et al. | Mar 1998 | A |
| 5738661 | Larice | Apr 1998 | A |
| 5807341 | Heim | Sep 1998 | A |
| 5830200 | Steer et al. | Nov 1998 | A |
| 5843053 | Steer | Dec 1998 | A |
| 5897531 | Amirana | Apr 1999 | A |
| 5931821 | Weilbacher et al. | Aug 1999 | A |
| 5954636 | Schwartz et al. | Sep 1999 | A |
| 5971962 | Kojima et al. | Oct 1999 | A |
| 5972026 | Laufer et al. | Oct 1999 | A |
| 6059816 | Moenning | May 2000 | A |
| 6083255 | Laufer et al. | Jul 2000 | A |
| 6174323 | Biggs et al. | Jan 2001 | B1 |
| 6197010 | Leise, Jr. et al. | Mar 2001 | B1 |
| 6200333 | Laufer | Mar 2001 | B1 |
| 6258100 | Alferness et al. | Jul 2001 | B1 |
| 6273907 | Laufer | Aug 2001 | B1 |
| 6283988 | Laufer et al. | Sep 2001 | B1 |
| 6283989 | Laufer et al. | Sep 2001 | B1 |
| 6287290 | Perkins et al. | Sep 2001 | B1 |
| 6293930 | Brunsgaard et al. | Sep 2001 | B1 |
| 6293951 | Alferness et al. | Sep 2001 | B1 |
| 6299633 | Laufer | Oct 2001 | B1 |
| 6322536 | Rosengart et al. | Nov 2001 | B1 |
| 6328689 | Gonzalez et al. | Dec 2001 | B1 |
| 6330882 | French | Dec 2001 | B1 |
| 6334441 | Zowtiak et al. | Jan 2002 | B1 |
| 6358269 | Aye | Mar 2002 | B1 |
| 6398775 | Perkins et al. | Jun 2002 | B1 |
| 6402754 | Gonzalez | Jun 2002 | B1 |
| 6411852 | Danek et al. | Jun 2002 | B1 |
| 6416554 | Alferness et al. | Jul 2002 | B1 |
| 6432100 | Affeld | Aug 2002 | B1 |
| 6443156 | Niklason et al. | Sep 2002 | B1 |
| 6468292 | Mollenauer et al. | Oct 2002 | B1 |
| 6485407 | Alferness et al. | Nov 2002 | B2 |
| 6488673 | Laufer et al. | Dec 2002 | B1 |
| 6491706 | Alferness et al. | Dec 2002 | B1 |
| 6514290 | Loomas | Feb 2003 | B1 |
| 6517519 | Rosen et al. | Feb 2003 | B1 |
| 6520183 | Amar | Feb 2003 | B2 |
| 6527761 | Soltesz et al. | Mar 2003 | B1 |
| 6543449 | Woodring et al. | Apr 2003 | B1 |
| 6550475 | Oldfield | Apr 2003 | B1 |
| 6569121 | Purow et al. | May 2003 | B1 |
| 6569166 | Gonzalez | May 2003 | B2 |
| 6585639 | Kotmel et al. | Jul 2003 | B1 |
| 6589161 | Corcoran | Jul 2003 | B2 |
| 6592594 | Rimbaugh et al. | Jul 2003 | B2 |
| 6599311 | Biggs et al. | Jul 2003 | B1 |
| 6609521 | Belani et al. | Aug 2003 | B1 |
| 6629951 | Laufer et al. | Oct 2003 | B2 |
| 6632239 | Snyder et al. | Oct 2003 | B2 |
| 6632243 | Zadno-Azizi et al. | Oct 2003 | B1 |
| 6634360 | Flodin | Oct 2003 | B1 |
| 6634363 | Danek et al. | Oct 2003 | B1 |
| 6638253 | Breznock | Oct 2003 | B2 |
| 6648862 | Watson | Nov 2003 | B2 |
| 6653525 | Ingenito et al. | Nov 2003 | B2 |
| 6659961 | Robinson | Dec 2003 | B2 |
| 6679264 | Deem et al. | Jan 2004 | B1 |
| 6682506 | Navarro | Jan 2004 | B1 |
| 6692494 | Cooper et al. | Feb 2004 | B1 |
| 6694979 | Deem et al. | Feb 2004 | B2 |
| 6695791 | Gonzalez | Feb 2004 | B2 |
| 6709401 | Perkins et al. | Mar 2004 | B2 |
| 6712812 | Roschak et al. | Mar 2004 | B2 |
| 6736797 | Larsen et al. | May 2004 | B1 |
| 6749606 | Keast et al. | Jun 2004 | B2 |
| 6770063 | Goldberg et al. | Aug 2004 | B2 |
| 6770070 | Balbierz | Aug 2004 | B1 |
| 6790172 | Alferness et al. | Sep 2004 | B2 |
| 6827086 | Shuman | Dec 2004 | B2 |
| 6837906 | Ginn | Jan 2005 | B2 |
| 6840243 | Deem et al. | Jan 2005 | B2 |
| 6843767 | Corcoran et al. | Jan 2005 | B2 |
| 6846292 | Bakry | Jan 2005 | B2 |
| 6849061 | Wagner | Feb 2005 | B2 |
| 6852108 | Barry et al. | Feb 2005 | B2 |
| 6860847 | Alferness et al. | Mar 2005 | B2 |
| 6878141 | Perkins et al. | Apr 2005 | B1 |
| 6886558 | Tanaka | May 2005 | B2 |
| 6901927 | Deem et al. | Jun 2005 | B2 |
| 6904909 | Andreas et al. | Jun 2005 | B2 |
| 6905518 | Ginn | Jun 2005 | B2 |
| 6916310 | Sommerich | Jul 2005 | B2 |
| 6929637 | Gonzalez et al. | Aug 2005 | B2 |
| 6941950 | Wilson et al. | Sep 2005 | B2 |
| 6997189 | Biggs et al. | Feb 2006 | B2 |
| 6997918 | Soltesz et al. | Feb 2006 | B2 |
| 7011094 | Rapacki et al. | Mar 2006 | B2 |
| 7014628 | Bousquet | Mar 2006 | B2 |
| 7022088 | Keast et al. | Apr 2006 | B2 |
| 7033387 | Zadno-Azizi et al. | Apr 2006 | B2 |
| 7036509 | Rapacki et al. | May 2006 | B2 |
| 7086398 | Tanaka | Aug 2006 | B2 |
| 7100616 | Springmeyer | Sep 2006 | B2 |
| 7135010 | Buckman et al. | Nov 2006 | B2 |
| 7141046 | Perkins et al. | Nov 2006 | B2 |
| 7165548 | Deem et al. | Jan 2007 | B2 |
| 7172581 | Ciok et al. | Feb 2007 | B2 |
| 7175644 | Cooper et al. | Feb 2007 | B2 |
| 7182772 | Alferness et al. | Feb 2007 | B2 |
| 7186259 | Perkins et al. | Mar 2007 | B2 |
| 7189225 | Rosen | Mar 2007 | B2 |
| 7192420 | Whiteford | Mar 2007 | B2 |
| 7195016 | Loyd et al. | Mar 2007 | B2 |
| 7195017 | Tanaka | Mar 2007 | B2 |
| 7207946 | Sirokman | Apr 2007 | B2 |
| 7232414 | Gonzalez | Jun 2007 | B2 |
| 7244245 | Purow et al. | Jul 2007 | B2 |
| 7252086 | Tanaka | Aug 2007 | B2 |
| 20010025132 | Alferness et al. | Sep 2001 | A1 |
| 20010041906 | Gonzalez | Nov 2001 | A1 |
| 20010041932 | Scholz et al. | Nov 2001 | A1 |
| 20020042564 | Cooper et al. | Apr 2002 | A1 |
| 20020062120 | Perkins et al. | May 2002 | A1 |
| 20020077593 | Perkins et al. | Jun 2002 | A1 |
| 20020087153 | Roschak et al. | Jul 2002 | A1 |
| 20020111619 | Keast et al. | Aug 2002 | A1 |
| 20020111620 | Cooper et al. | Aug 2002 | A1 |
| 20020112729 | DeVore et al. | Aug 2002 | A1 |
| 20020165618 | Ingenito et al. | Nov 2002 | A1 |
| 20020188171 | Alferness et al. | Dec 2002 | A1 |
| 20030013935 | Alferness et al. | Jan 2003 | A1 |
| 20030018344 | Kaji et al. | Jan 2003 | A1 |
| 20030050648 | Alferness et al. | Mar 2003 | A1 |
| 20030051733 | Kotmel et al. | Mar 2003 | A1 |
| 20030055331 | Kotmel et al. | Mar 2003 | A1 |
| 20030065339 | Snyder et al. | Apr 2003 | A1 |
| 20030069488 | Alferness et al. | Apr 2003 | A1 |
| 20030078469 | Corcoran | Apr 2003 | A1 |
| 20030083542 | Alferness et al. | May 2003 | A1 |
| 20030083671 | Rimbaugh et al. | May 2003 | A1 |
| 20030127090 | Gifford et al. | Jul 2003 | A1 |
| 20030130593 | Gonzalez | Jul 2003 | A1 |
| 20030149446 | Shuman | Aug 2003 | A1 |
| 20030154988 | DeVore et al. | Aug 2003 | A1 |
| 20030158515 | Gonzalez et al. | Aug 2003 | A1 |
| 20030163024 | Corcoran | Aug 2003 | A1 |
| 20030181356 | Ingenito | Sep 2003 | A1 |
| 20030181922 | Alferness | Sep 2003 | A1 |
| 20030183235 | Rimbaugh et al. | Oct 2003 | A1 |
| 20030186904 | Ruben et al. | Oct 2003 | A1 |
| 20030195385 | DeVore | Oct 2003 | A1 |
| 20030195511 | Barry | Oct 2003 | A1 |
| 20030212337 | Sirokman | Nov 2003 | A1 |
| 20030212412 | Dillard et al. | Nov 2003 | A1 |
| 20030216730 | Barry et al. | Nov 2003 | A1 |
| 20030216769 | Dillard et al. | Nov 2003 | A1 |
| 20030228344 | Fields et al. | Dec 2003 | A1 |
| 20030233099 | Danaek et al. | Dec 2003 | A1 |
| 20040010209 | Sirokman | Jan 2004 | A1 |
| 20040010289 | Biggs et al. | Jan 2004 | A1 |
| 20040016435 | Deem et al. | Jan 2004 | A1 |
| 20040024356 | Tanaka | Feb 2004 | A1 |
| 20040031494 | Danek et al. | Feb 2004 | A1 |
| 20040040555 | Tanaka | Mar 2004 | A1 |
| 20040047855 | Ingenito | Mar 2004 | A1 |
| 20040055606 | Hendricksen et al. | Mar 2004 | A1 |
| 20040059263 | DeVore et al. | Mar 2004 | A1 |
| 20040073155 | Laufer et al. | Apr 2004 | A1 |
| 20040073191 | Soltesz et al. | Apr 2004 | A1 |
| 20040073201 | Cooper et al. | Apr 2004 | A1 |
| 20040073241 | Barry et al. | Apr 2004 | A1 |
| 20040078026 | Wagner | Apr 2004 | A1 |
| 20040078054 | Biggs et al. | Apr 2004 | A1 |
| 20040097983 | Snyder et al. | May 2004 | A1 |
| 20040143282 | Dillard et al. | Jul 2004 | A1 |
| 20040144387 | Amar | Jul 2004 | A1 |
| 20040158228 | Perkins et al. | Aug 2004 | A1 |
| 20040167636 | Dillard et al. | Aug 2004 | A1 |
| 20040173218 | Yamada et al. | Sep 2004 | A1 |
| 20040200484 | Springmeyer | Oct 2004 | A1 |
| 20040206349 | Alferness et al. | Oct 2004 | A1 |
| 20040210248 | Gordon et al. | Oct 2004 | A1 |
| 20040211412 | Alferness et al. | Oct 2004 | A1 |
| 20040211434 | Loomas et al. | Oct 2004 | A1 |
| 20040220446 | Corcoran et al. | Nov 2004 | A1 |
| 20040220556 | Cooper et al. | Nov 2004 | A1 |
| 20040225254 | Tanaka et al. | Nov 2004 | A1 |
| 20040231674 | Tanaka | Nov 2004 | A1 |
| 20040237966 | Tanaka | Dec 2004 | A1 |
| 20040243140 | Alferness et al. | Dec 2004 | A1 |
| 20040244802 | Tanaka | Dec 2004 | A1 |
| 20040244803 | Tanaka | Dec 2004 | A1 |
| 20050005936 | Wondka | Jan 2005 | A1 |
| 20050015106 | Perkins et al. | Jan 2005 | A1 |
| 20050022809 | Wondka | Feb 2005 | A1 |
| 20050025816 | Tanaka | Feb 2005 | A1 |
| 20050033310 | Alferness et al. | Feb 2005 | A1 |
| 20050033344 | Dillard et al. | Feb 2005 | A1 |
| 20050043745 | Alferness et al. | Feb 2005 | A1 |
| 20050043751 | Phan et al. | Feb 2005 | A1 |
| 20050043752 | Phan et al. | Feb 2005 | A1 |
| 20050049615 | Cooper et al. | Mar 2005 | A1 |
| 20050056292 | Cooper | Mar 2005 | A1 |
| 20050060041 | Phan et al. | Mar 2005 | A1 |
| 20050060042 | Phan et al. | Mar 2005 | A1 |
| 20050060044 | Roschak et al. | Mar 2005 | A1 |
| 20050061322 | Freitag | Mar 2005 | A1 |
| 20050066976 | Wondka | Mar 2005 | A1 |
| 20050085801 | Cooper et al. | Apr 2005 | A1 |
| 20050096529 | Cooper et al. | May 2005 | A1 |
| 20050103340 | Wondka | May 2005 | A1 |
| 20050107783 | Tom et al. | May 2005 | A1 |
| 20050131276 | Alferness et al. | Jun 2005 | A1 |
| 20050137518 | Biggs et al. | Jun 2005 | A1 |
| 20050137611 | Escudero et al. | Jun 2005 | A1 |
| 20050137712 | Biggs et al. | Jun 2005 | A1 |
| 20050137715 | Phan et al. | Jun 2005 | A1 |
| 20050145253 | Wilson et al. | Jul 2005 | A1 |
| 20050161040 | Tanaka | Jul 2005 | A1 |
| 20050166925 | Wilson et al. | Aug 2005 | A1 |
| 20050171396 | Pankratov et al. | Aug 2005 | A1 |
| 20050177144 | Phan et al. | Aug 2005 | A1 |
| 20050178385 | Dellaca′ et al. | Aug 2005 | A1 |
| 20050178389 | Shaw et al. | Aug 2005 | A1 |
| 20050192526 | Biggs et al. | Sep 2005 | A1 |
| 20050203483 | Perkins et al. | Sep 2005 | A1 |
| 20050205097 | Kyle, Jr. | Sep 2005 | A1 |
| 20050244401 | Ingenito | Nov 2005 | A1 |
| 20050281797 | Gong et al. | Dec 2005 | A1 |
| 20050281801 | Gong et al. | Dec 2005 | A1 |
| 20050281802 | Gong et al. | Dec 2005 | A1 |
| 20050282748 | Gong et al. | Dec 2005 | A1 |
| 20050288549 | Mathis | Dec 2005 | A1 |
| 20050288550 | Mathis | Dec 2005 | A1 |
| 20050288684 | Aronson et al. | Dec 2005 | A1 |
| 20050288702 | McGurk et al. | Dec 2005 | A1 |
| 20060004400 | McGurk et al. | Jan 2006 | A1 |
| 20060009748 | Mathis | Jan 2006 | A1 |
| 20060025815 | McGurk et al. | Feb 2006 | A1 |
| 20060047291 | Barry | Mar 2006 | A1 |
| 20060076023 | Rapacki et al. | Apr 2006 | A1 |
| 20060079838 | Walker et al. | Apr 2006 | A1 |
| 20060095002 | Soltesz et al. | May 2006 | A1 |
| 20060107961 | Tanaka | May 2006 | A1 |
| 20060116749 | Willink et al. | Jun 2006 | A1 |
| 20060118125 | Tanaka | Jun 2006 | A1 |
| 20060118126 | Tanaka | Jun 2006 | A1 |
| 20060124126 | Tanaka | Jun 2006 | A1 |
| 20060130830 | Barry | Jun 2006 | A1 |
| 20060135947 | Soltesz et al. | Jun 2006 | A1 |
| 20060135984 | Kramer et al. | Jun 2006 | A1 |
| 20060142672 | Keast et al. | Jun 2006 | A1 |
| 20060161233 | Barry et al. | Jul 2006 | A1 |
| 20060162731 | Wondka et al. | Jul 2006 | A1 |
| 20060206147 | DeVore et al. | Sep 2006 | A1 |
| 20060212046 | Pearce et al. | Sep 2006 | A1 |
| 20060212051 | Snyder et al. | Sep 2006 | A1 |
| 20060235432 | DeVore et al. | Oct 2006 | A1 |
| 20060235467 | DeVore | Oct 2006 | A1 |
| 20060264772 | Aljuri et al. | Nov 2006 | A1 |
| 20060276807 | Keast et al. | Dec 2006 | A1 |
| 20060280772 | Roschak et al. | Dec 2006 | A1 |
| 20060280773 | Roschak et al. | Dec 2006 | A1 |
| 20060283462 | Fields et al. | Dec 2006 | A1 |
| 20070005083 | Sabanathan et al. | Jan 2007 | A1 |
| 20070027434 | Pedersen et al. | Feb 2007 | A1 |
| 20070043350 | Soltesz et al. | Feb 2007 | A1 |
| 20070051372 | Tanaka | Mar 2007 | A1 |
| 20070055175 | Caro | Mar 2007 | A1 |
| 20070088300 | Cline et al. | Apr 2007 | A1 |
| 20070123922 | Cooper et al. | May 2007 | A1 |
| 20070128174 | Kleinsek et al. | Jun 2007 | A1 |
| 20070142742 | Aljuri et al. | Jun 2007 | A1 |
| 20070163598 | Chang et al. | Jul 2007 | A1 |
| 20070185531 | Rimbaugh et al. | Aug 2007 | A1 |
| 20070186932 | Wondka et al. | Aug 2007 | A1 |
| 20070186933 | Domingo et al. | Aug 2007 | A1 |
| Number | Date | Country |
|---|---|---|
| 0260543 | Apr 1987 | EP |
| 0260543 | Mar 1988 | EP |
| 0609950 | Oct 1994 | EP |
| 1 393 760 | Mar 2004 | EP |
| 2192185 | Oct 2002 | RU |
| WO 8801879 | Mar 1988 | WO |
| WO 9004982 | May 1990 | WO |
| 9945990 | Sep 1999 | WO |
| WO 9945990 | Sep 1999 | WO |
| WO 9966975 | Dec 1999 | WO |
| WO 9966975 | Dec 1999 | WO |
| WO 0076577 | Dec 2000 | WO |
| 0102042 | Jan 2001 | WO |
| WO 0102042 | Jan 2001 | WO |
| WO 0145568 | Jun 2001 | WO |
| WO 02076279 | Oct 2002 | WO |
| WO 02096325 | Dec 2002 | WO |
| WO 03007821 | Jan 2003 | WO |
| 03020338 | Mar 2003 | WO |
| WO 03020338 | Mar 2003 | WO |
| WO 03061480 | Jul 2003 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20040237966 A1 | Dec 2004 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60473999 | May 2003 | US |
